Navigation Links
Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
Date:10/29/2009

ance to Amicus."

Amicus will continue to manage global clinical operations for Amigal Phase 3 development and expects to initiate more than thirty investigational sites worldwide. As previously announced, the first global Phase 3 Amigal study is a 60 patient randomized, double-blind placebo controlled six month study intended to support U.S. registration. The primary surrogate endpoint agreed to with the U.S. Food and Drug Administration (FDA) is a histological evaluation of the change in GL-3 levels in the interstitial capillary cells of the kidney. The first patient was randomized into this study in mid-October. The Company estimates it will complete enrollment for this trial by the end of 2010 and expects to have data available in mid-2011. A separate Phase 3 study for registration in the European Union comparing Amigal with Fabrazyme® is required by the European Medicines Agency (EMEA). Amicus expects to provide a further update on that proposed study for the EMEA in 2010 as the supply constraints with Fabrazyme become clearer.

Key Strategic Priorities and Workforce Reduction:

As part of its strategic business plan, Amicus will focus its resources in three key areas:

  • The Phase 3 development of Amigal for Fabry disease;
  • Advancement of its lead pre-clinical programs that utilize its pharmacological chaperone technology for the treatment of diseases of neurodegeneration. The Company has an advanced pre-clinical program in Parkinson's disease, as well as an earlier stage pre-clinical program in an as yet undisclosed neurodegenerative target disease; and
  • Advancement of pharmacological chaperones used in combination with enzyme replacement therapies (ERT) for the treatment of lysosomal storage diseases.

"By focusing our resources on these three value creating centers within Amicus, we will balance the execution of our global late stage clinical program in Fabry di
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... , April 23, 2015 Prospects ...   Report Details   We predict ... value of $101.3 billion in 2015 and will grow at ... in the healthcare sectors around the world and increasing functional ... growth factors in the global healthcare packaging market. ...
(Date:4/23/2015)... 2015  Metanome, Inc., an industry leader in ... changed its name to Diversigen, Inc.  The name ... single commercial source for the myriad of services ... diverse opportunities of the microbiome.  From the wide ... including those that are difficult to handle, such ...
(Date:4/23/2015)... ReliantHeart's HeartAssist5® Ventricular Assist Device (VAD) precisely measure ... in real time, and this data is uploaded to ... Machine to Machine (M2M) communications for the Internet of ... can be monitored by a patient’s clinician 24/7, ... a minimum threshold, the patient can be notified immediately. ...
(Date:4/22/2015)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ) today reported ... For the first quarter ended March 31, 2015, ... or $0.08 per share, compared to a net loss ... same period in 2014. As of March 31, 2015, ... interest receivable of $226.1 million. Revenues for ...
Breaking Biology Technology:Healthcare Packaging Market Forecast 2015-2025 2Healthcare Packaging Market Forecast 2015-2025 3Healthcare Packaging Market Forecast 2015-2025 4Healthcare Packaging Market Forecast 2015-2025 5Healthcare Packaging Market Forecast 2015-2025 6Healthcare Packaging Market Forecast 2015-2025 7Healthcare Packaging Market Forecast 2015-2025 8Healthcare Packaging Market Forecast 2015-2025 9Healthcare Packaging Market Forecast 2015-2025 10Metanome Announces Corporate Name Change to Diversigen 2Sangamo BioSciences Reports First Quarter 2015 Financial Results 2Sangamo BioSciences Reports First Quarter 2015 Financial Results 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 4Sangamo BioSciences Reports First Quarter 2015 Financial Results 5Sangamo BioSciences Reports First Quarter 2015 Financial Results 6Sangamo BioSciences Reports First Quarter 2015 Financial Results 7Sangamo BioSciences Reports First Quarter 2015 Financial Results 8
... Hu of China - Source: Getty Images The Olympics ... four years. They're held every year. Though this is still ... as the pervasive growth of the industry becomes part of ... every four years and last two weeks, the biotech Olympics ...
... MADISON, Wis. - Ownership and accountability is the way ... 448-bed community hospital in Madison that provides medical care ... living facility, laboratories and a home health care service. ... Methodist Hospital in 1987, Meriter includes more than 430 ...
... trend three years ago many companies cut their information ... the price of computers dropped, allowing businesses to inexpensively ... grew. Many IT staffers are wary of returning to ... looked to begin working as an outside IT source, ...
Cached Biology Technology:The Olympics: A Biotech Perspective 2The Olympics: A Biotech Perspective 3Meriter IT team builds project performance through internal relationships 2Meriter IT team builds project performance through internal relationships 3Meriter IT team builds project performance through internal relationships 4Expetec expands IT staff services in Wisconsin 2Expetec expands IT staff services in Wisconsin 3
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/10/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) ... Profiles - NEC" report to their offering. ... continue to supply a range of IT security management ... focus on the development of a Big Data and ... the Asia-Pacific region is a ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... screening the genome of hundreds of thousands of individuals ... more than 100 regions in the genome to the ... Molecular Biology Laboratory (EMBL) and the University of Heidelberg, ... taking these results one step further by pinpointing the ...
... 2013) "Green" chemistry developed at Rice University is at ... waste into fatty acids, and then into fuel. The ... recently announced $25 million United States Department of Agriculture project ... products from switchgrass and forestry residues and from a new ...
... have been a source of great controversyparticularly in Europebut ... scientific evidence about the health and ecological impacts of ... field site dedicated for use in GM crop studies ... interested in pursuing crop biotechnology, according to an article ...
Cached Biology News:Zeroing in on heart disease 2Modified bacteria turn waste into fat for fuel 2Modified bacteria turn waste into fat for fuel 3Fighting GM crop vandalism with a government-protected research site 2
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
Biology Products: